Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.
Sign Up to like & getrecommendations! Published in 2019 at "European urology"
DOI: 10.1016/j.eururo.2018.12.015
Abstract: BACKGROUND Abiraterone and enzalutamide are associated with side effects that may impair health-related quality of life (HRQoL). OBJECTIVE To assess patient-reported HRQoL, depression symptoms, and cognitive function for abiraterone versus enzalutamide. DESIGN, SETTING, AND PARTICIPANTS… read more here.
Keywords: fact; abiraterone; versus enzalutamide; quality life ... See more keywords
Adverse Events of Abiraterone Acetate Versus Enzalutamide.
Sign Up to like & getrecommendations! Published in 2023 at "Urology practice"
DOI: 10.1097/upj.0000000000000404
Abstract: PURPOSE To highlight the comprehensive differences in adverse events (AEs) between abiraterone (ABI) and enzalutamide (ENZ) based on a big data dataset. MATERIALS AND METHODS We downloaded AE datasets of ABI and ENZ from the… read more here.
Keywords: acetate versus; abiraterone acetate; abi enz; events abiraterone ... See more keywords
Risk of heart failure with abiraterone versus enzalutamide amongst patients diagnosed with metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.e24029
Abstract: e24029 Background: Abiraterone and enzalutamide are key androgen receptor-targeted therapies for metastatic castration-resistant prostate cancer (mCRPC); however, their comparative cardiovascular safety, particularly the risk of heart failure (HF), remains unclear in older patients. This systematic… read more here.
Keywords: versus enzalutamide; meta analysis; abiraterone versus; analysis ... See more keywords